Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

about

Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.

Item

http://www.wikidata.org/entity/Q47821919

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Utility of molecular tools for ...... isions in early breast cancer.

@en

Utility of molecular tools for ...... isions in early breast cancer.

@nl

type

Item

label

Utility of molecular tools for ...... isions in early breast cancer.

@en

Utility of molecular tools for ...... isions in early breast cancer.

@nl

prefLabel

Utility of molecular tools for ...... isions in early breast cancer.

@en

Utility of molecular tools for ...... isions in early breast cancer.

@nl

P1476

Utility of molecular tools for ...... isions in early breast cancer.

@en

P2093

Domen Ribnikar

http://www.w3.org/2001/XMLSchema#string

P2860

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncolog

Factors predicting late recurrence for estrogen receptor-positive breast cancer

Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.

Extended adjuvant endocrine therapy - A standard to all or some?

P304

2733-2736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.2217/FON-2017-0427

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philippe L. Bedard

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29168649

http://www.w3.org/2001/XMLSchema#string